Novel Two-Prong Biologic Shows Promise in Asthma

The unique dual inflammation blockade of investigational lunsekimig showed promise for moderate-to-severe asthma in the phase II AIRCULES study.

Targeting both thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13, lunsekimig at various doses achieved statistically significant reductions in asthma attacks, with a 55.3% reduction in exacerbations at 48 weeks when comparing the highest dose of 300 mg every 28 days against placebo (P=0.0016).

This was supported by secondary endpoints favoring lunsekimig at this dose, reported Njira Lugogo, MD, of the University of Michigan in Ann Arbor, at the European Respiratory Society (ERS) Congress in Barcelona.

"This trial is very impactful," Lugogo said. "Lunsekimig achieved a statistically significant and clinically meaningful reduction in asthma exacerbations. You saw a change in lung function that was rapid and sustained. Patient-centric outcomes also improved, and improvements were observed across subgroups, with a greater magnitude of response in those with greater disease severity, including frequent exacerbations. It was well tolerated at all doses."

"Results from this phase II study support dual TSLP and IL-13 targeting to address unmet needs in individuals with moderate to severe asthma," she concluded.